Skip to main
DGX

Quest Diagnostics (DGX) Stock Forecast & Price Target

Quest Diagnostics (DGX) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 9%
Buy 27%
Hold 64%
Sell 0%
Strong Sell 0%

Bulls say

Quest Diagnostics is poised for strong growth in the upcoming years as their core trends, including revenue, adjusted EPS, and AOI, continue to surpass expectations. The company's recent partnerships, such as the FMS and Corewell deals, are expected to drive significant revenue growth in 2026. Additionally, the company's strong performance in the physician channel, with high single-digit growth and expanded health plan access, provides potential for continued volume growth. Despite potential headwinds, such as weather and increased investment, DGX maintains a strong financial position with solid cash flow and a healthy balance sheet.

Bears say

Quest Diagnostics is poised for growth with strong first quarter results, beating both top and bottom-line estimates and increasing guidance for FY26. With strong organic volumes and growth in Advanced Diagnostics, as well as investments in AI and automation, the company is well-positioned for future success. Despite solid cash flow and a strong M&A/partnership pipeline, the negative outlook remains due to potential challenges in the healthcare industry such as potential regulation changes and competition from emerging companies.

Quest Diagnostics (DGX) has been analyzed by 11 analysts, with a consensus rating of Hold. 9% of analysts recommend a Strong Buy, 27% recommend Buy, 64% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Quest Diagnostics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Quest Diagnostics (DGX) Forecast

Analysts have given Quest Diagnostics (DGX) a Hold based on their latest research and market trends.

According to 11 analysts, Quest Diagnostics (DGX) has a Hold consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $232, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $232, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Quest Diagnostics (DGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.